- Symeres has expanded its integrated spray drying capabilities at its Cranbury, New Jersey CMC development site to support formulation development for poorly soluble and development-challenged small molecule drug candidates.
- The investment adds laboratory-scale and pilot-scale spray drying capabilities and integrates formulation, analytical, solid-state science, and process development services within a single site.
Symeres has expanded its integrated spray drying capabilities at its Cranbury, New Jersey Chemistry, Manufacturing and Controls (CMC) development site. The investment is intended to support formulation development for poorly soluble and development-challenged small molecule drug candidates and help biotechnology and pharmaceutical companies advance programs from preclinical development through Phase II clinical studies.
The expanded capability is designed to support bioavailability enhancement strategies, including amorphous solid dispersions (ASDs), particle engineering, and solubility optimization. According to the company, the investment strengthens its integrated CMC offering by combining spray drying, formulation sciences, analytical characterization, solid-state sciences, and process development within a single scientific environment.
The Cranbury facility now supports both laboratory-scale and pilot-scale spray drying workflows. Symeres said these capabilities enable material screening, process optimization, and scalable process development, particularly for Biopharmaceutical Classification System (BCS) Class II and IV compounds, highly lipophilic molecules, and targeted therapies requiring enhanced oral exposure.
“An increasing proportion of modern small molecule drug candidates require advanced formulation approaches to achieve acceptable bioavailability and clinical performance.”
Paul O’Shea, Managing Director at Exemplify BioPharma, a Symeres company
The expanded capability supports formulation feasibility studies, IND-enabling development, clinical trial material supply, process optimization, and technology transfer. Symeres said the investment reflects growing demand for integrated development partners that can support discovery, API development, formulation sciences, and analytical activities through a coordinated scientific framework.
